AgomAb Therapeutics NV (AGMB) Key Metrics
AGMB key metrics, 2022–2025
Fiscal year ended December 31, 2025 · eurosAGMB returns How much profit the business earns on the capital it uses.
AGMB financial health Debt, liquidity and how easily interest is covered.
AGMB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AGMB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AGMB key metrics in euros
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Returns & profitability | ||||
| Return on equity (ROE) | −39.2% | −27.3% | −10.5% | −12.3% |
| Return on invested capital (ROIC) | −290.3% | −166.2% | −72.9% | −46.3% |
| Return on assets (ROA) | −34.7% | −24.5% | −8.4% | −8.1% |
| Return on tangible assets | −52.1% | −26.0% | −8.0% | −11.3% |
| Financial health | ||||
| Total debt | €1.3M | — | — | — |
| Cash & short-term investments | €116.5M | €171.5M | €122.4M | €27.7M |
| Net debt | −€115.3M | −€171.5M | −€122.4M | −€27.7M |
| Debt / equity | 0.01 | — | — | — |
| Debt / assets | 0.01 | — | — | — |
| Current ratio | 6.52 | 19.05 | 12.81 | 2.39 |
| Quick ratio | 6.52 | 19.05 | 12.81 | 2.39 |
| Interest coverage | -987.9 | -716.7 | — | -503.0 |
| Working capital | €102.6M | €164.7M | €128.6M | €41.4M |
| Invested capital | €15.6M | €16.6M | €29.0M | €38.6M |
| Tangible asset value | €97.2M | €159.4M | €122.7M | €37.5M |
| Net current asset value | €98.4M | €155.6M | €119.7M | €36.3M |
| Capital allocation | ||||
| Capex / depreciation | 0.02 | 2.17 | 0.00 | 0.00 |
| Efficiency | ||||
| Days payables outstanding | 11,781.7 | — | — | — |
| Receivables turnover | 0.00 | — | — | — |
| Payables turnover | 0.03 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | €4.8M | — | — | — |
| Average payables | €6.8M | €6.4M | €5.4M | €3.9M |
| Intangibles / total assets | 21.9% | 13.9% | 16.8% | 28.4% |
Computed from AGMB's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in euros; data from EODHD. Averages use the opening and closing balance of each year.
AGMB valuation and financial ratios
AgomAb Therapeutics NV earned a return on equity of −39.2% and a return on invested capital of −290.3% in fiscal 2025. It ended the year with €1.3 million of debt and €116.5 million in cash and short-term investments, a net cash position of €115.3 million.
See the AGMB income statement, the AGMB chart for price history, or the AGMB stock overview for the latest quote and news.
AGMB key metrics FAQ
What is AgomAb Therapeutics NV's return on equity?
AgomAb Therapeutics NV's return on equity (ROE) was −39.2% in fiscal 2025: net income of -€62.5 million on average shareholders' equity of €159.5 million.
What is AgomAb Therapeutics NV's ROIC?
AgomAb Therapeutics NV's return on invested capital was −290.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does AgomAb Therapeutics NV have?
AgomAb Therapeutics NV had total debt of €1.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is AgomAb Therapeutics NV's current ratio?
AgomAb Therapeutics NV's current ratio was 6.52 at the end of fiscal 2025: current assets were 6.52 times current liabilities.